Investor Relations

To Our Stakeholders

Net Sales and All Income Categories Reach Historical Highs, Driven Mainly by Strong Overseas Performance

China, EMEA*1 and All Other Geographic Regions Deliver Double-Digit Sales Increases
Sharply Higher Income, Benefiting from Effects of Higher Sales and Yen Depreciation

During the first nine months of the fiscal year ending March 31, 2015, net sales expanded on strong overseas performance, achieving double-digit growth. Furthermore, income benefited significantly from the effects of higher sales and the impact of a weaker yen.

Net sales rose 20.0% year on year, with operating income up 42.5%, ordinary income up 43.1% and net income up 47.3%. At the exchange rates prevailing one year earlier, net sales would have been up 14.2% and operating income up 23.5%.

In Japan, sales in the hematology*2 and immunochemistry fields grew resulting in a slight increase. Overseas, sales were strong in all geographic regions, including China and the EMEA region, achieving double-digit growth on a local currency and yen basis. Particularly in China, sales of instruments and reagents grew as market needs in the hematology and hemostasis fields increased, resulting in significant sales growth, up 32.9% year on year. Sales also grew overseas, driving the Sysmex Group’s overseas sales ratio to 81.8%.

In terms of performance during the first nine months, although sales and income were higher than the same period in the previous fiscal year, we expect performance in the fourth quarter will proceed according to initial forecasts. Thus, we maintain unchanged our consolidated financial forecast for the full fiscal year ending March 31, 2015, as announced in November 2014.

One of our key initiatives in the third quarter was the launch of the LC-1000 exfoliative cell analyzer, which aims to enhance the efficiency of future cervical cancer screening tests*3.
Going forward, Sysmex intends to proactively promote research and development, provide testing with high clinical value and contribute to the development of healthcare.

*1 Europe, the Middle East and Africa

*2 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

*3 Screening test: Process for distinguishing between items that require precise testing and those that do not.

Hisashi Ietsugu
Chairman and CEO


Related Links
 - Presentation
 - Financial Data
 - Financial Statement


President and CEO Hisashi Ietsugu
February 2015 
Hisashi Ietsugu
Chairman and CEO
Hisashi Ietsugu

Top of Investor Relation

Sysmex Corporation

Copyright© SYSMEX CORPORATION, All Rights Reserved.